Acer Therapeutics to Participate in March Virtual Investor Conferences
Get Alerts ACER Hot Sheet
Join SI Premium – FREE
NEWTON, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will present and host one-on-one investor meetings at the upcoming H.C. Wainwright Global Life Sciences Virtual Conference and the 33rd Annual Roth Virtual Conference.
Conference: | H.C. Wainwright Global Life Sciences Virtual Conference |
Dates: | March 9-10, 2021 |
Format: | One-on-one virtual meetings |
Conference: | 33rd Annual Roth Virtual Conference |
Format: | Panel Presentation and one-on-one virtual meetings |
Panel: | Therapeutics Against SARS-CoV-2 |
Date: | Monday, March 15, 2021 |
Time: | 12 p.m. Eastern Time |
Webcast: | https://acertx.com/investor-relations/events-presentations/ |
About Acer Therapeutics Inc.Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acer’s pipeline includes four programs: ACER-001 (sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); EDSIVO™ (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms (iVMS); and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. Each of Acer’s product candidates is believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the FDA. For more information, visit www.acertx.com.
Investor Contact:Hans VitzthumLifeSci AdvisorsPh: 617-430-7578[email protected]
Jim DeNikeAcer Therapeutics Inc.Ph: 844-902-6100[email protected]
Source: Acer Therapeutics Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ROCKWOOL A/S – transactions in connection with share buy-back programme
- UAB „Atsinaujinančios energetikos investicijos“ publishes audited consolidated and separate annual financial statements for 2023
- Group 1 Automotive Reports First Quarter 2024 Financial Results
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Definitive Agreement, H.C. Wainwright, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!